MedTrace Logo

Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer

NCT03125603 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-02-19

No results posted yet for this study

Summary

The immune-related adverse events (irAEs) linked to the important activation of the immune system by new immunotherapy treatments in patients affected by Non-small-cell lung carcinoma (NSCLC) have not received a lot of systematic study or been monitored over time outside of clinical trials.

This study aims to verify, on the basis of the data collected in a prospective and retrospective manner, that the side-effects due of anti-PD-(L)-1 or anti-CTLA-4 treatments observed in the target population of the controlled clinical trials are the same as in the general clinical population.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Drug-Related Side Effects and Adverse Reactions

Interventions

OTHER

Consultation of the patient's medical files at the hospital

Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Thierry Pieters, MD, PhD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-13
Primary Completion
2018-08-01
Completion
2018-08-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03125603 on ClinicalTrials.gov